Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jonathan Miller

MOHS-Micrographic Surgery Ooltewah, TN Medical Doctor

NPI 1346637048 CMS profile 2476769

5243 Little Debbie Pkwy Ste 111, Ooltewah, TN 37363

Open in the dashboard

General payments

$4,217

211 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Miller of Ooltewah, TN is reported in the CMS Open Payments database as having received $4,217 across 211 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,194 60
2024 General $986 52
2023 General $1,036 51
2022 General $592 30
2021 General $373 16
2020 General $35 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Miller
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Jonathan Miller were reported at $1,194. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Jonathan Miller MOHS-Micrographic Surgery median Middle half National median
2019 $0 $316 $106–$785 $163
2020 $35 $162 $68–$412 $114
2021 $373 $243 $87–$654 $132
2022 $592 $300 $102–$887 $149
2023 $1,036 $364 $125–$1,010 $160
2024 $986 $445 $142–$1,108 $164
2025 $1,194 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Lilly USA, LLC $676 39 payments
  2. Novartis Pharmaceuticals Corporation $625 36 payments
  3. AbbVie, Inc. $579 26 payments
  4. Sun Pharmaceutical Industries Inc. $524 29 payments
  5. Genzyme Corporation $230 8 payments
  6. Janssen Biotech, Inc. $222 10 payments
  7. Sientra, Inc. $147 1 payment
  8. Galderma Laboratories, L.P. $136 10 payments
  9. UCB, Inc. $131 5 payments
  10. E.R. Squibb & Sons, L.L.C. $129 7 payments
  11. Other $817 40 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,217 211 payments
Products named General payments · program years 2020–2025
  1. TALTZ $500 34 payments
  2. ILUMYA $410 22 payments
  3. COSENTYX Dermatology $391 21 payments
  4. RINVOQ $300 12 payments
  5. DUPIXENT $230 8 payments
  6. TREMFYA $222 10 payments
  7. COSENTYX Immunology $213 14 payments
  8. SIMPONI ARIA $150 6 payments
  9. STELARA $150 6 payments
  10. SIMPONI $150 6 payments
  11. Other $1,917 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,505

Median for Micrographic Dermatologic Surgery: 314

Drug cost

$24,016

Median for Micrographic Dermatologic Surgery: $3,836

Branded share of claims

2.2%

Median for Micrographic Dermatologic Surgery: 1.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 91 $6,400
Fluorouracil Generic 66 $5,239
Mupirocin Generic 618 $4,457
Doxycycline Hyclate Generic 406 $3,021
Ketoconazole Generic 73 $1,272
Triamcinolone Acetonide Generic 93 $935
Fluocinonide Generic 18 $610
Dapsone Generic 14 $553
Clindamycin Phosphate Generic 13 $524
Valacyclovir Valacyclovir Hcl Brand 22 $429

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 366 Part D prescribers listed as Micrographic Dermatologic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$717,586

Of which drugs: $6,182

Medicare patients

1,072

Average age 76

Services billed

5,418

511 women, 561 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 45%
Ischemic heart disease 31%
Diabetes 27%
Atrial fibrillation 21%
Chronic kidney disease 20%
Cancer 16%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 11 20 $6,120

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ILUMYA
  • Sun Pharmaceutical Industries Inc. $129
$129 — —
TALTZ
  • Lilly USA, LLC $121
$121 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $88
$88 — —
RINVOQ
  • AbbVie, Inc. $86
$86 — —
Bimzelx
  • UCB, Inc. $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

211 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record